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Abstract A mutant of echistatin, a disintegrin with a high 
affinity for the integrins, was constructed by substituting 
CRGDC for ARGDIJ in the Arg-Gly-Asp (RGD) region. The 
mutant was chemically synthesized, subjected to a folding process 
with air oxidation, and purified by reverse-phase HPLC. The 
peptide mapping and mass spectrometric analyses revealed that 
the two Cys residues introduced in the mutant are linked to each 
other, without any effect on the mode of the four disultide bonds 
present in native ecblstatin, as expected. The mutant strongly 
inhibited the binding of human fibrinogen to its receptor, integrin 
aIn,p3, with an I&, value of 0.12 nM. This value shows that the 
mutant is twice as potent as the native form (IQ, = 0.23 &I). 
These results indicate that the native disintegrin molecule, which 
has been considered to possess the optimum affinity for the 
integrins, can be tailored to exhibit even higher affinity by 
introducing the conformational constraint into the RGD region. 
Monte Carlo simulations of KRCRGDCMD, the RGD region in 
the mutant, suggested that the disulfide bond constrains the RGD 
region to assume a type II’ p-turn, with Gly and Asp in positions 
2 and 3 of the turn. 
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1. Introduction 
Recently, a number of potent integrin antagonists, the dis- 
integrins, have been isolated from the venom of various vi- 
pers. These proteins include echistatin [l] from Echis carina- 
tus, kistrin [2] from Agkistrodon rhodostroma, trigramin [3] 
from Trimeresurus gramineus, and others. They are cysteine- 
rich, 50-80 residue proteins, and all contain a functional Arg- 
Gly-Asp (RGD) sequence. It is known that they inhibit plate- 
let aggregation, through the binding to integrin an&, 500- 
1000 times more strongly than the GRGDS peptide [2,4]. 
Pierschbacher and Ruoslahti reported that G-Pen- 
GRGDSPCA, in which Pen, penicillamine, forms a disulfide 
bond with Cys, can inhibit the adhesion of normal rat kidney 
cells to vitronectin more effectively than the linear peptide, 
GRGDSPC [5]. It was also described that cyclo(GRGDSPA) 
is a much better inhibitor of the adhesion of B16 melanoma 
cells to vitronectin or fibronectin than the linear counterpart, 
GRGDSPA [6]. These results indicate that it is possible to 
increase the affinity to the integrins by introducing a confor- 
mational constraint into an RGD-containing peptide. 
In this study, we examined whether this strategy is also 
applicable to a natural protein with a high integrin affinity. 
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We have constructed a mutant molecule by placing two Cys 
residues at the positions flanking RGD in echistatin, a disin- 
tegrin composed of 49 amino acid residues [7]. Here we report 
the successful formation of a new disulfide bond between the 
introduced Cys residues in the mutant, and its functional eva- 
luation. Modeling of the RGD conformation in the mutant by 
a Monte Carlo simulation is also shown. 
2. Materials and methods 
2.1. Chemical synthesis 
Starting with 0.08 mm01 (0.8 g) of Fmoc-Thr(tBu)-NovaSyn KA 
resin (0.1 mmoYg), the synthesis of mutant echistatin was carried out 
in a stepwise manner using the LKB automated peptide synthesizer, 
Biolynx 4170. The amino acids were introduced using the manufac- 
turer’s cartridges (0.25 mmol each). Side chain protection was arginine 
(Mtr), aspartic acid (OtBu), cysteine (Trt), glutamic acid (OtBu), his- 
tidine (Trt), lysine (Boc), serine (tBu), threonine (tBu), tyrosine (tBu) 
(Mtr, 4-methoxy-2,3,6-trimethylphenyl-sulfonyl; OtBu, tert-butyl es- 
ter; Trt, trityl; Boc, tert-butyloxycarbonyl; tBu, tert-butyl). 
2.2. TFA cleavage and air oxidation 
The assembled resin (1.3 g) was suspended in a mixture of TFA (42 
ml), anisole (3 ml), and ethane-dithiol (2 ml), in a flat-bottomed flask. 
After stirring at room temperature for 12 h, the reaction mixture was 
concentrated on a rotary evaporator. The residue was triturated with 
cold ether, filtered, and washed three times with cold ether. The fil- 
tered residue was dissolved in 2 N acetic acid and freeze-dried. The 
crude product was purified on an A-303 ODS column (2X 30 cm, 
YMC). 
The air oxidation of the protein was carried out as described by 
Garsky et al. [8]. The solution was acidified to pH 3.0 by the addition 
of acetic acid and pumped directly onto a Shodex ODSpak F-411/S 
column (0.46~ 10 cm, Showa-dencoh, Japan). The oxidized protein 
product was eluted at a flow rate of 0.8 GYmin with a 60-min linear 
gradient of acetonitrile increasing from 5% to 25% in 0.1% TFA. The 
oxidized form of the mutant echistatin was obtained with a yield of 
0.5 mg. 
2.3. Binding assay 
Native echistatin was purchased from Sigma. The concentrations of 
the mutant and the native echistatin were determined according to the 
results of the amino acid analyses. Two RGD-containing peptides, 
GRGDSP and cyclo(Arg-Gly-Asp-DPhe-Val), were purchased from 
Peptide Institute (Japan). 
The inhibitory effects of these molecules on the binding of fibrino- 
gen to immobilized integrin anbPs were examined as described pre- 
viously [9]. 
2.4. Peptide mapping analysis 
The mutant or the native echistatin (0.2 mg each) was dissolved in 
1.0 ml of 25 mM Tris-1 mM EDTA, pH 8.3, and digested with 10 pg 
of endoproteinase Lys-C (Wake Pure Chemicals, Japan) at 37°C for 5 
h. The BrCN treatment was carried out in 1.0 ml of 70% formic acid 
with 0.3 mg of BrCN at room temperature for 20 h. The resultant 
peptides were separated by reverse-phase HPLC and identified by 
amino acid analyses and N-terminal sequence analyses. 
2.5. Analysis of N-terminal amino acid sequence 
The N-terminal amino acid sequence was determined, using an 
Applied Biosystems Model 477A sequencer equipped with a 120A 
online PTH amino acid analyzer. 
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2.6. Analysis of amino acid composition 
The amino acid composition was determined on a 24-h hydrolysate 
with 6 N HCI at 110°C in the presence of 4% thioglycolic acid. Amino 
acid analysis using ninhydrin was performed on a Hitachi Model 835 
amino acid analyzer. 
2.7. Mass spectrometry 
The electrospray ionization (ESI) mass spectrum was measured with 
a JEOL JMS-HXl 10/l 10A double-focusing mass spectrometer 
equipped with an ES1 ion source (Analytica, Branford, CT) [9]. 
Each of the echistatins (200 pmol) was dissolved in 20 pl of HzO/ 
acetic acid/acetonitrile (5: 1:4) and infused into the ion source at a 
flow rate of 1 PVmin. 
The fast-atom bombardment (FAB) mass spectrum was obtained 
using the above spectrometer equipped with an FAB ion source. The 
sample (0.5 nmol) was dissolved in water-acetonitrile (1: l), mixed 
with a liquid matrix (a mixture of dithiothreitol and dithioerythritol, 
5:l w/w), and bombarded with xenon atoms accelerated at a 6-kV 
potential in the ion source. 
2.8. Monte Carlo simulation 
The Monte Carlo (MC) simulations of the two RGD-containing 
peptide fragments, KRARGDDMD (residues 21-29) from the native 
echistatin and KRCRGDCMD (residues 21-29) from the mutant, 
were carried out by the program FEDER [lo] with the ECEPPR force 
field [l l] at 1000 K. In order to improve the acceptance ratio of the 
ring structure formation of the mutant, we adopted the scaled collec- 
tive variable MC method [12]. This method effectively samples con- 
formations that satisfy the ring closure of the disulfide bond between 
the two Cys residues. The high-temperature simulation allows sam- 
pling of all possible conformations. In addition to the ECEPP/2 po- 
tential, a harmonic distance restraint of 3 kcal/mol is imposed between 
the two Ca atoms of Lys-21 and Asp-29 to maintain the average 
distance of the NMR structures [13]. This had little influence on the 
RGD conformations. A total of lo7 MC steps were accumulated for 
each peptide. 
2.9. CIassiJcation of the sampled conformations 
The sampled conformations were grouped into three classes in 
terms of the ($, v) region of the Gly residue [14]. This classification 
is consistent with a cluster analysis of RGD conformations in terms of 
the root-mean square deviation, because the conformation is mostly 
determined by the ($I, v) angles of Gly. The three classes are char- 
acterized by the distance d between the CD atoms of Arg-24 and Asp- 
26, and by the conformation of Gly-25. Class 1: d=9.%-9.5 A; Giy 
A I 
I -I 
[M+5H16+ 
J097.9 
988 l0e0 I I@a 
m/z 
conformation=E, F, E*, or F’. Class 2: kI=7.5-8.5 A; Gly con- 
formation=C’ or D*. Class 3: d= 5.5-6.0 A; Gly conformation=C, 
A*, or B” [9]. The conformational regions are designated according to 
Zimmerman et al. [14]. 
3. Results 
The mutant echistatin with the RGD sequence flanked by 
two Cys residues was chemically synthesized, in vitro folded 
with air oxidation, and purified by reverse-phase HPLC, as 
described in section 2. The mutant thus obtained eluted as a 
single peak, with a similar retention time to that of native 
echistatin (from Sigma) on analytical reverse-phase HPLC. 
The N-terminal amino acid sequence of the mutant, as deter- 
mined up to 20 residues by the automated Edman degradation 
method, was identical with that of the native form. The amino 
acid composition of the mutant was in good agreement with 
the theoretical values (data not shown). 
On the electrospray mass spectrometric analysis, the mutant 
(Fig. 1A) and the native form (Fig. 1B) produced two multi- 
ply-charged ion signals, [M+5H15’ and [M+6H16+. These ion 
signals for the mutant and the native form gave calculated 
average molecular weights of 5434.7 kO.2 and 5416.7 f0.2, 
respectively. These values are in good accordance with their 
theoretical molecular weights, 5435.2 and 5417.1, indicating 
that no modification occurs on these molecules. In addition, 
no free thiol group was detected in the mutant by the dithio- 
bis(2-nitrobenzoic acid) method [15]. These results show that 
all of the 10 Cys residues in the mutant are linked via five 
disulfide bonds. 
The locations of the disulfide bonds were examined by pep- 
tide mapping analyses. When digested by endoproteinase Lys- 
C, peptide fragment L (see Fig. 2B), lacking FLK (residues 
13-15) and GPAT (residues 4&49), was isolated by reverse- 
phase HPLC. Fragment L from the mutant was further treat- 
ed with BrCN, resulting in the formation of fragment B-I, 
RCRGDCM (Fig. 2), while the same treatment of the native 
[M+5Hlb 
1884. 
[M+Hl+ 
790.145 
m/z mlz 
Fig. 1. Electrospray mass spectra of mutant (A) and native (B) echistatins. The mass of each echistatin was calculated from the m/z values of 
the two multiply-charged ion signals, [M+5H15+ and [M+6H16+. (C) Fast-atom bombardment mass spectrum of fragment B-I. The B-I fragment 
(see Fig. 2A) produced a main molecular ion ([M+H]+) with an m/z value of 790.145, which is in good agreement with the theoretical value 
(790.3) of the cyclic form of RCRGDCM with C-terminal homoserine lactone in place of the Met residue. The signal marked by an asterisk is 
derived from the linear counterpart, which was produced by reduction of the disulfide bond during mass measurement. 
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Fig. 2. BrCN treatment of the Lys-C digest (fragment L) from the 
mutant echistatin. (A) Elution pattern after BrCN cleavage of fag- 
ment L on reverse-phase HPLC. The BrCN-treated products from 
fragment L (50 Kg) were applied to a Shodex ODSpak F-4116 col- 
umn (0.46X 10 cm). Elution was performed with a linear gradient of 
acetonitrile concentration in the presence of 0.1% TFA, at a flow 
rate of 0.8 ml/mm. (B) Identification of each peptide fragment. 
Fragments B-I, B-II, and L were identified by amino acid analyses 
and N-terminal sequence analyses. Dots show the positions of Cys 
residues. 
echistatin produced the fragment RARGDDM. The C-ter- 
minal Met residues from RCRGDCM and RARGDDM, of 
course, were converted into homoserine lactone after the 
BrCN reaction. In both cases, the recovery of the heptapep- 
tides was about 70%, according to the amino acid analyses. 
This value is consistent with the fact that a considerable 
amount of the starting peptide fragment L was detected after 
the BrCN reaction. Fragment B-II (Fig. 2) eluted with the 
same retention time as the corresponding fragment from the 
native echistatin on the HPLC. These results reveal that the 
two Cys residues introduced in the mutant are linked to each 
other without any effects on the four disulfide bonds in the 
native form [7]. The presence of the new disulfide bond in the 
mutant was further confirmed by FAB mass spectrometry of 
the B-I fragment (Fig. 1C). 
We examined the affinity level of the mutant echistatin to 
the integrins. For this purpose, integrin a&s was purified 
from human erythroleukemia cell line HEL (ATCC TIB 
180) by chromatography on columns of ConA-Sepharose, 
GRGDSPK-Sepharose, and Sephacryl S-300. After these 
steps, highly purified integrin o.tr& was obtained with a yield 
of 1 mg per 10 liters of culture medium. We finally established 
a binding assay system using the integrin and biotinylated 
fibrinogen, as described in section 2. The binding assay 
showed that the mutant is twice as potent (ICs0=0.12 nM) 
as the native echistatin (IC50=0.23 nM) (Fig. 3). The results 
indicate that the introduction of a conformational constraint 
into the RGD region of the echistatin molecule significantly 
increases the affinity to the integrin, as in an RGD-containing 
peptide. In addition, it should be noted that these echistatin 
molecules are much more effective than a short peptide, 
GRGDSP (ICss=120 nM) or cyclo(Arg-Gly-Asp-DPhe-Val) 
(ICss=6.8 nM) (data not shown). 
The influence of the introduced disulfide bond on the RGD 
conformation was investigated by Monte Carlo simulations of 
the two RGD-containing peptide fragments, KRARGDDMD 
(residues 21-29) from the native echistatin and 
KRCRGDCMD (residues 21-29) from the mutant. The 
sampled conformations were classified into three structural 
classes in terms of the (I$, v) region of the Gly residue (see 
section 2): class 1 has a fully extended Gly residue; class 2 
assumes a type II’ B-turn having a hydrogen bond between 
the C=O of Arg-24 and the H-N of Cys-27 (Asp-27 for the 
native form); and class 3 is characterized by a salt bridge 
between the two side chains of Arg-24 and Asp-26. The MC 
simulations show that classes 1, 2, and 3 were sampled with 
probabilities of 0.15, 0.29, and 0.22 for the native fragment 
and 0.13, 0.52, and 0.13 for the mutant fragment. The disul- 
fide bond increases the occurrence of class 2 by about lOO%, 
while the other two classes are rather suppressed. The results 
suggest that the most probable conformation of the mutant 
fragment belongs to class 2 assuming a type II’ p-turn, with 
Gly and Asp in positions 2 and 3 of the turn. A snapshot of 
the mutant fragment with the type II’ B-turn conformation is 
shown in Fig. 4. 
4. Discussion 
It has been shown that the cyclic form of an RGD-contain- 
ing peptide has much higher affinity for integrins than the 
linear counterpart [5,6]. Recently, we constructed a mutant 
lysozyme, Cys-RGD4, by inserting RGDS flanked by two 
Cys residues, and found that the Cys-RGD4 possesses higher 
cell adhesion activity than the RGDS-inserted lysozyme, 
RGD4 [9,16]. In these cases, the conformational constraint 
in the RGD region effectively increased the affinity for the 
integrins. However, these RGD-containing cyclic molecules 
1.0 - 
0 
I 
0” 0.05 0.1 0.5 Edhistatin (nM) 
Fig. 3. Inhibitory effect of each echistatin on the binding of fibrino- 
gen to integrin a&s. The plastic substrates were coated with 1 pg/ 
ml integrin-air&, and 1 nIv4 biotinylated fibrinogen was incubated 
on the substrates for 3 h at 30°C in the presence of different con- 
centrations of the mutant (0) and the native echistatin (0). The 
ICss value of each echistatin is defined as the concentration neces- 
sary to inhibit receptor binding by 50%. 
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Fig. 4. Molscript drawing of a snapshot of KRCRGDCMD assuming the type II’ p-turn conformation [21]. Main chain atoms are represented 
by black balls. Only the side chains of CRGDC are shown as white balls. The RGD residues are indicated by shaded sticks. The type II’ p- 
turn is characterized by a hydrogen bond between the C = 0 of Arg-24 and the H-N of Cys-27; the distance between 0 of Arg-24 and N of 
Cys-27 is 2.9 A in this-stru&re.- 
have a lo-fold lower affinity than the natural cell adhesive 
proteins including the disintegrins [2,5,9]. The purpose of 
this study was to address the question of whether the confor- 
mational constraint works also in a natural disintegrin, echis- 
tatin. The results obtained here prove that this strategy is 
significantly effective in the disintegrin, which possesses an 
affinity comparable to that of the ligand protein, fibrinogen 
[I]. It is noteworthy that the affinity can be improved beyond 
the level that has been considered to be optimal. 
Monte Carlo simulations suggest that the disulfide bond 
constrains the RGD region to assume a type II’ p-turn, 
with Gly and Asp in positions 2 and 3 of the turn (Fig. 4). 
It is easy to explain why the disulfide bond enhances the 
occurrence of the turn conformation. The disulfide bond 
forms a small 17-atom-membered ring in the RGD region. 
This covalent structure does not favor theQdistance d (CD of 
Arg-CD of Asp) to be either more than 9 A or less than 6 A. 
A value of d that is too large causes difficulty in maintaining 
the ring structure, and a d value that is too small may produce 
unfavorably dense atom packing. It is natural to conclude 
that the formation of the type II’ p-turn structure in RGD 
is the reason for the increase of the binding affinity of the 
mutant. 
This conformation has been found in the RGD regions of 
several proteins. We have recently solved the X-ray crystal 
structure of the CRGDSC-inserted lysozyme, Cys-RGD4. 
The RGD sequence in this protein resides within a stable 
type II’ p-turn, with a hydrogen bond between the C=O of 
Arg and the H-N of Ser [17]. The fibronectin type III domain 
from human tenascin [18] and the leech protein decorsin [19], 
each of which does not contain a Cys residue neighboring the 
RGD, also have similar structures in their RGD regions. 
It has been suggested that the C-terminal portion of echis- 
tatin, in addition to the RGD region, would be important in 
the interaction with integrin a~& [13]. This speculation 
agrees with the idea that the integrin an& contains an un- 
recognized exosite other than the RGD binding site [20]. 
Thus, in the case of the present mutant echistatin, the RGD 
region with the type II’ p-turn conformation, in cooperation 
with the C-terminal portion, could bind to the integrin with 
an extremely high affinity. 
In the present investigation, we have succeeded in tailoring 
echistatin to possess higher affinity for integrin a&s. The 
strategy described here can be also applied to other members 
of the disintegrins. 
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